Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It treats chemotherapy‑induced nausea and vomiting and postoperative nausea and vomiting in patients undergoing cancer therapy or surgery.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Kytril (granisetron) is used to control nausea and vomiting mediated by serotonin receptors.

Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of acute and delayed episodes. Post‑operative nausea and vomiting: prevents nausea and vomiting after surgical procedures. Radiation‑induced nausea and vomiting: helps manage nausea following radiation therapy.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - QT interval prolongation leading to cardiac arrhythmia - Severe allergic reaction (anaphylaxis)

Before prescribing Kytril, clinicians should consider the following precautions: - Cardiac history: patients with known QT prolongation should be monitored. - Concomitant serotonergic drugs: avoid additive effects that may increase serotonin levels. - Hepatic impairment: dose may need adjustment in severe liver disease. - Constipation: monitor for severe constipation that could require intervention. - Pregnancy and breastfeeding: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Major Interactions (Avoid): - Other QT‑prolonging agents: may increase risk of cardiac arrhythmia. - CYP3A4 inhibitors (e.g., ketoconazole): may raise granisetron plasma levels. - Serotonin reuptake inhibitors (SSRIs, SNRIs): potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may enhance constipation. - CYP2D6 substrates: may have altered metabolism. - Overlapping antiemetics (e.g., ondansetron): may increase adverse effect burden.